Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Guidance Raises Prospect Of More INDs For Supplement Research

This article was originally published in The Tan Sheet

Executive Summary

An FDA draft guidance that seeks to clarify when an investigational new drug application should be filed may add logistical knots to the process of studying foods and dietary ingredients, stakeholders say.

You may also be interested in...



Resveratrol Partners Asks For IND Waiver On Macular Degeneration Claim

Resveratrol Partners submitted a petition that argues FDA regulations slow the development of health care products to address public health needs, such as the treatment of wet age-related macular degeneration. “It’s the public’s welfare, it’s not about rules and regulations,” says the firm’s managing partner, Bill Sardi.

Resveratrol Partners Asks For IND Waiver On Macular Degeneration Claim

Resveratrol Partners submitted a petition that argues FDA regulations slow the development of health care products to address public health needs, such as the treatment of wet age-related macular degeneration. “It’s the public’s welfare, it’s not about rules and regulations,” says the firm’s managing partner, Bill Sardi.

OTC Probiotics Face Challenging Regulatory Framework

The development of OTC drugs based on probiotics requires a regulatory system more receptive to research on the microorganisms' use as therapeutic ingredients, according to microbiologist Gary Huffnagle.

Related Content

Topics

UsernamePublicRestriction

Register

PS104799

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel